Experience with nusinersen as a pathogenetic therapy in adult patients with spinal muscular atrophy 5q in the Republic of Bashkortostan
Background. Spinal muscular atrophy (SMA) affects 1 in 11,000 people. Until 2016, this was considered an incurable disease, but after the approval of nusinersen, the situation has changed. The efficacy of nusinersen therapy is also known in adult patients, although research is limited due to the maj...
Saved in:
| Main Authors: | S. V. Umutbaev, L. Sh. Murzabaeva, M. A. Kutlubaev, A. V. Shishigin, T. N. Sharipov, E. V. Sayfullina, R. V. Мagzhanov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2023-03-01
|
| Series: | Нервно-мышечные болезни |
| Subjects: | |
| Online Access: | https://nmb.abvpress.ru/jour/article/view/528 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Experience of Nusinersen in children with proximal spinal muscular atrophy 5q in Moscow region
by: M. V. Panteleeva
Published: (2022-12-01) -
A cross-sectional and longitudinal evaluation of serum creatinine as a biomarker in spinal muscular atrophy
by: Xin Zhao, et al.
Published: (2024-12-01) -
Common complications in spinal muscular atrophy (SMA) type 1 after nusinersen treatment
by: Yiğithan Güzin, et al.
Published: (2024-11-01) -
Molecular markers of disease severity and response to nusinersen therapy in 5q spinal muscular atrophy (literature review)
by: K. D. Popov, et al.
Published: (2023-10-01) -
Impact of Nusinersen on the Health-Related Quality of Life and Caregiver Burden in Patients with Spinal Muscular Atrophy with Symptom Onset before the Age of 6 Months
by: Yun Jeong Lee, et al.
Published: (2025-04-01)